US 12,258,403 B2
Methods for treating myeloma by achieving therapeutically effective doses of anti-CD47 antibody
Stephen Willingham, Sammamish, WA (US); Maureen Howard, Los Altos Hills, CA (US); Jie Liu, Palo Alto, CA (US); Ravindra Majeti, Palo Alto, CA (US); Susan Sweeney Prohaska, Mountain View, CA (US); Anne K. Volkmer, Duesseldorf (DE); Jens-Peter Volkmer, Menlo Park, CA (US); and Irving L. Weissman, Stanford, CA (US)
Assigned to The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US)
Filed by The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US)
Filed on Feb. 3, 2023, as Appl. No. 18/164,252.
Application 16/375,238 is a division of application No. 15/423,325, filed on Feb. 2, 2017, granted, now 10,301,387, issued on May 28, 2019.
Application 18/164,252 is a continuation of application No. 17/734,904, filed on May 2, 2022, granted, now 11,603,404.
Application 17/734,904 is a continuation of application No. 17/401,046, filed on Aug. 12, 2021.
Application 17/401,046 is a continuation of application No. 17/102,183, filed on Nov. 23, 2020, granted, now 11,136,391, issued on Aug. 31, 2021.
Application 17/102,183 is a continuation of application No. 16/375,238, filed on Apr. 4, 2019, granted, now 11,104,731, issued on Oct. 5, 2021.
Application 15/423,325 is a continuation of application No. 14/769,069, granted, now 9,623,079, issued on Apr. 18, 2017, previously published as PCT/US2014/018743, filed on Feb. 26, 2014.
Claims priority of provisional application 61/800,102, filed on Mar. 15, 2013.
Prior Publication US 2023/0303688 A1, Sep. 28, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); A61K 38/17 (2006.01); C07K 16/28 (2006.01); A61K 38/18 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2803 (2013.01) [A61K 38/1774 (2013.01); A61K 39/3955 (2013.01); C07K 16/2896 (2013.01); A61K 38/1816 (2013.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2319/30 (2013.01); Y02A 50/30 (2018.01)] 19 Claims
OG exemplary drawing
 
1. A method for treating myeloma in a human subject, the method comprising:
(a) administering a sub-therapeutic dose of an anti-CD47 antibody or a fragment thereof to the subject, wherein the sub-therapeutic dose is capable of increasing production of reticulocytes; and
(b) administering a therapeutically effective dose of the anti-CD47 antibody or the fragment thereof to the subject,
wherein the anti-CD47 antibody or the fragment thereof blocks an interaction between CD47 and SIRPα, wherein the myeloma is treated.